Yakob Liawatidewi Sells 13,980 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock

Share on StockTwits

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) SVP Yakob Liawatidewi sold 13,980 shares of the company’s stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $21.50, for a total value of $300,570.00. Following the sale, the senior vice president now owns 48,963 shares of the company’s stock, valued at approximately $1,052,704.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Yakob Liawatidewi also recently made the following trade(s):

  • On Wednesday, November 28th, Yakob Liawatidewi sold 1,520 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $20.49, for a total value of $31,144.80.
  • On Friday, November 23rd, Yakob Liawatidewi sold 1,299 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $20.26, for a total value of $26,317.74.
  • On Friday, November 9th, Yakob Liawatidewi sold 17,808 shares of Amphastar Pharmaceuticals stock. The stock was sold at an average price of $20.97, for a total value of $373,433.76.

NASDAQ AMPH opened at $21.47 on Thursday. Amphastar Pharmaceuticals Inc has a twelve month low of $14.40 and a twelve month high of $22.74. The company has a quick ratio of 1.34, a current ratio of 2.02 and a debt-to-equity ratio of 0.10. The stock has a market cap of $989.73 million, a P/E ratio of 56.50 and a beta of 1.42.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, November 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. The business had revenue of $75.54 million during the quarter, compared to analysts’ expectations of $76.84 million. During the same quarter in the previous year, the firm earned $0.07 EPS. The firm’s revenue was up 30.5% compared to the same quarter last year. As a group, analysts expect that Amphastar Pharmaceuticals Inc will post -0.06 EPS for the current year.

Institutional investors have recently bought and sold shares of the business. Piedmont Investment Advisors LLC acquired a new position in Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $128,000. SG Americas Securities LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $161,000. Nisa Investment Advisors LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $221,000. Paloma Partners Management Co acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $223,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $295,000. 44.74% of the stock is owned by hedge funds and other institutional investors.

AMPH has been the subject of several recent analyst reports. BidaskClub downgraded Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 13th. Needham & Company LLC decreased their price target on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 10th. ValuEngine upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 17th. Wells Fargo & Co reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, November 9th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $26.00 price target on shares of Amphastar Pharmaceuticals in a research note on Wednesday, November 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $23.60.

COPYRIGHT VIOLATION NOTICE: “Yakob Liawatidewi Sells 13,980 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock” was originally published by Zolmax and is owned by of Zolmax. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://zolmax.com/investing/yakob-liawatidewi-sells-13980-shares-of-amphastar-pharmaceuticals-inc-amph-stock/2744306.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Further Reading: How analysts view the yield curve

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Washington Real Estate Investment Trust Declares Quarterly Dividend of $0.30
Washington Real Estate Investment Trust Declares Quarterly Dividend of $0.30
Brokerages Set Information Services Group, Inc.  Price Target at $5.25
Brokerages Set Information Services Group, Inc. Price Target at $5.25
Akzo Nobel  Receives Consensus Recommendation of “Buy” from Analysts
Akzo Nobel Receives Consensus Recommendation of “Buy” from Analysts
Recent Research Analysts’ Ratings Updates for Mimecast
Recent Research Analysts’ Ratings Updates for Mimecast
Liquidity Network Price Tops $0.0383 on Major Exchanges
Liquidity Network Price Tops $0.0383 on Major Exchanges
Centrica PLC  Receives Average Recommendation of “Hold” from Brokerages
Centrica PLC Receives Average Recommendation of “Hold” from Brokerages


Leave a Reply

 
© 2006-2018 Zolmax.